The quest to radically extend human healthspan just got a significant boost. NewLimit, the biotechnology company tackling age-related diseases, has secured $435.0M in new funding to accelerate its ambitious research.
NewLimit is developing medicines by reprogramming the epigenome, a novel therapeutic mechanism aimed at restoring regenerative potential in aged and diseased cells. The company leverages functional genomics, pooled perturbation screening, and machine learning models, conducting experiments of unprecedented scale to unravel the complex biology of epigenetic aging and disease.
